Overall verdict
Neutral
3.7/10
1-year performance
+37.52%
Score breakdown
Up 37.5% over 1 year, 57% of the 52-week range.
Strongest: Growth 7.4/10. Weakest: Valuation 0.0/10.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Six
Switzerland
CEO
Mr. Orlando Oliveira
Founded
2004
Employees
94
Revenue / employee
824 626 CHF
Next earnings
December 11, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
18.84 CHF
52-week low
10.12 CHF
1-year performance
37.52%
Rising
Year-to-date performance
12.69%
Rising
Drawdown
-19.85%
Marked drawdown
Position in the 52-week range
57% of range
Range: 25.00 CHF - 30.00 CHF (2 methods agree)
The price implies growth of 46.70% per year; the company grows at 25.00%.
Gross margin 40.3%, the company loses 31.5% of its revenue, ROIC -51.9%, ROE 416.7%.
Net margin
-31.46%
Negative
Sector -208.32%|S&P 13.40%
Gross margin
40.26%
High
Return on equity (ROE)
416.69%
Exceptional
Sector -57.84%|S&P 17.06%
Return on invested capital (ROIC)
-51.90%
Negative
Free cash flow margin (FCF)
0.56%
Low
Margin stability
1147.9 pts
Very uneven
Revenue to net income
Growth
7.4/10Revenue up 101.3% over 1 year, 38.8% a year over 5.
Revenue (trailing 12 months)
99.5M CHF
Revenue growth (1y)
101.30%
Hyper-growth
Revenue growth (3y)
932.85%
Hyper-growth
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector 0.88|S&P 0.91
Fair value (reverse DCF)
27.50 CHF
Deeply undervalued
Market cap
227M CHF
Financial strength
6.3/10Cash covers 47.1% of the debt, net debt/EBITDA 0.1x.
Net debt / EBITDA
0.1x
Very solid
Gearing (net debt / equity)
—
Cash
41.0M CHF
Cash / market cap
18.02%
Very solid
Cash / total debt
47.08%
Solid
Interest coverage
-0.5x
Stretched
Net debt
46.1M CHF
Equity
-6.1M CHF
Closed daily candles, 2 years
Last close on November 11, 2026: 14.84 CHF
- MM2014.81
- MM5015.12
- MM20015.62
- RSI 1449.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.19%
200-day average slope, 3 months
+7.16%
50-day average slope, 1 month
-2.90%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.60 % per day
Volatility change
-9.49%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | — | -1.60 (2) | 95 (2) | -21 (1) | — |
| 2027 | — | 0.22 (2) | 116 (2) | 8 (1) | — |
Amounts in millions of CHF, EPS in CHF per share. In brackets, the number of analysts. Consensus as of November 6, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | SANN | 3.7 | 3.2 | 273M USD | Not meaningful (loss) | -31.5 % | 101.3 % | -51.9 % | 0.1x | 0.2 % | 37.5 % | ||
| 5 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 6 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -44.2 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
